SCHEMBL10110936

SCHEMBL10110936

Cc1ccc(C)c(-c2ccncc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 1/20 0.49
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
RECQL P46063 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
LRRK2 Q5S007 1/20 0.42
GCGR P47871 1/20 0.41
MAPK14 Q16539 1/20 0.41
ESRRA P11474 1/20 0.41
BTK Q06187 1/20 0.41
CYP19A1 P11511 2/20 0.41
CYP11B2 P19099 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30720274 1.00 CYP46A1 (0.49) CYP46A1PDE3BPDE3ANPC1RAB9A
SCHEMBL10110954 0.96 CYP46A1 (0.46) CYP46A1PDE3BPDE3ANPC1RAB9A
SCHEMBL3422005 0.84 CYP46A1 (0.54) CYP46A1PDE3BPDE3ANPC1RAB9A
SCHEMBL25871395 0.84 CYP46A1 (0.54) CYP46A1PDE3BPDE3ANPC1RAB9A
SCHEMBL13393498 0.83 NPC1 (0.60) CYP46A1PDE3BPDE3ANPC1RAB9A
SCHEMBL1046094 0.81 ESRRA (0.46) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL21627244 0.81 PDE3B (0.55) CYP46A1PDE3BPDE3ANPC1RAB9A
SCHEMBL139182 0.81 ESRRA (0.46) MEN1KMT2AALDH1A1ESRRATDP1
SCHEMBL30445989 0.81 ESRRA (0.46) MEN1KMT2AALDH1A1ESRRATDP1
SCHEMBL8065159 0.79 MAPK14 (0.51) PDE3BPDE3AGCGRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117164872-A Preparation method and application of Zn-MOF catalyst with post-synthesis modified pore canal 沈阳化工大学 2023-12-05 CN claimed
CN-117069925-A Preparation method and application of modified PBAT (Poly-p-phenylene diamine) by taking bio-based acid as raw material 沈阳化工大学 2023-11-17 CN claimed
CN-116874753-A Preparation method of nano metal organic catalyst for synthesizing PBAT (Poly-p-phenylene-co-terephthalate) 沈阳化工大学 2023-10-13 CN claimed
CN-117164872-A Preparation method and application of Zn-MOF catalyst with post-synthesis modified pore canal 沈阳化工大学 2023-12-05 CN disclosed
CN-117164872-A Preparation method and application of Zn-MOF catalyst with post-synthesis modified pore canal 沈阳化工大学 2023-12-05 CN disclosed
CN-117069925-A Preparation method and application of modified PBAT (Poly-p-phenylene diamine) by taking bio-based acid as raw material 沈阳化工大学 2023-11-17 CN disclosed
CN-116874753-A Preparation method of nano metal organic catalyst for synthesizing PBAT (Poly-p-phenylene-co-terephthalate) 沈阳化工大学 2023-10-13 CN disclosed
CN-116874753-A Preparation method of nano metal organic catalyst for synthesizing PBAT (Poly-p-phenylene-co-terephthalate) 沈阳化工大学 2023-10-13 CN disclosed
WO-2023280177-A1 SMALL MOLECULE COMPOUND TARGETING BCL9/β-CATENIN INTERACTION 南通聚太生物科技有限公司 2023-01-12 WO disclosed
US-9758688-B2 Composition for forming conductive film SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-09-12 US disclosed
US-9704612-B2 Composition of silver-conjugated compound composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-11 US disclosed
US-20150275015-A1 COMPOSITION FOR FORMING CONDUCTIVE FILM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-10-01 US disclosed
US-8866134-B2 Light-emitting device and photovoltaic cell, and method for manufacturing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-10-21 US disclosed
US-20130099224-A1 LIGHT-EMITTING DEVICE AND PHOTOVOLTAIC CELL, AND METHOD FOR MANUFACTURING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-04-25 US disclosed
US-20120168693-A1 SILVER-(CONJUGATED COMPOUND) COMPOSITE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-05 US disclosed
US-20120168693-A1 SILVER-(CONJUGATED COMPOUND) COMPOSITE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-05 US disclosed
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-09 US disclosed
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-09 US disclosed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF CDH1, EPCAM, CD4 CYP46A1 1304/4885PDE3B 4873/4885PDE3A 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.